Associated Papers
Structural Analysis of Janus Tyrosine Kinase Variants in Hematological Malignancies: Implications for Drug Development and Opportunities for Novel Therapeutic Strategies.
Rodriguez Moncivais OJ et al.
International Journal of Molecular Sciences, 2023
p.Y317H is a new JAK2 gain-of-function mutation affecting the FERM domain in a myelofibrosis patient with CALR mutation.
Eder-Azanza L et al.
Haematologica, 2017
Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides.
McGirt LY et al.
Blood, 2015
JAK/STAT signaling in hematological malignancies.
Vainchenker W et al.
Oncogene, 2013
Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma.
Koo GC et al.
Cancer Discovery, 2012
FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma.
Elliott NE et al.
Blood, 2011
Select a paper to view details